Sevelamer carbonate in the management of hyperphosphatemia

ISSN： 1475-0708

Source： Therapy, Vol.5, Iss.4, 2008-07, pp. : 545-552

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia

By Pai A.B. Smeeding J.E. Brook R.A.

Current Medical Research and Opinion, Vol. 20, Iss. 7, 2004-07 ,pp. : 991-999

Informa Healthcare

Access to resources Recommend Favorite

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

By Thompson Melissa

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 744-755

Informa Healthcare

Access to resources Recommend Favorite

Sevelamer

Nephron Clin Pract, Vol. 94, Iss. 3, 2004-11 ,pp. : c53-c58

Karger

Access to resources Recommend Favorite

Efficacy, Tolerability, and Safety of Lanthanum Carbonate in Hyperphosphatemia: A 6-Month, Randomized, Comparative Trial versus Calcium Carbonate

Nephron Clin Pract, Vol. 100, Iss. 1, 2005-04 ,pp. : c8-c19

Karger

Access to resources Recommend Favorite

Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 5, 2015-10 ,pp. : 471-476

John Wiley & Sons Inc

Access to resources Recommend Favorite